BTK and neoplasm: Although these studies suggested that BTK inhibitors and PI3K inhibitors may not be ideally suited for counteracting venetoclax resistance when tumor cells are residing in protective niches, it is important to note that these inhibitors are highly effective at mobilizing tumor cells out of those niches into peripheral circulation.